Acumen Pharmaceuticals Inc (ABOS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Acumen Pharmaceuticals Inc (ABOS) has a cash flow conversion efficiency ratio of -0.271x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.10 Million) by net assets ($70.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Acumen Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Acumen Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ABOS total liabilities for a breakdown of total debt and financial obligations.
Acumen Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Acumen Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Epsilon Energy Ltd
NASDAQ:EPSN
|
0.040x |
|
GAMSUNG Corporation Co. Ltd
KQ:036620
|
-0.037x |
|
Sriracha Construction Public Company Limited
BK:SRICHA
|
0.699x |
|
Les Hotels Bav
PA:ALLHB
|
0.002x |
|
KGL Resources Ltd
AU:KGL
|
-0.009x |
|
Oando PLC
JSE:OAO
|
-0.158x |
|
Readly International AB
ST:READ
|
0.372x |
|
HB Technology CO.LTD
KQ:078150
|
0.041x |
Annual Cash Flow Conversion Efficiency for Acumen Pharmaceuticals Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Acumen Pharmaceuticals Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see ABOS company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $70.43 Million | $-115.54 Million | -1.640x | -245.95% |
| 2024-12-31 | $181.82 Million | $-86.22 Million | -0.474x | -193.97% |
| 2023-12-31 | $266.97 Million | $-43.06 Million | -0.161x | +13.38% |
| 2022-12-31 | $188.78 Million | $-35.15 Million | -0.186x | -133.47% |
| 2021-12-31 | $225.18 Million | $-17.96 Million | -0.080x | -119.90% |
| 2020-12-31 | $-18.59 Million | $-7.45 Million | 0.401x | -32.88% |
| 2019-12-31 | $-11.42 Million | $-6.82 Million | 0.597x | -- |
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target s… Read more